{
    "clinical_study": {
        "@rank": "85685", 
        "arm_group": [
            {
                "arm_group_label": "10 Second Delay", 
                "arm_group_type": "Active Comparator", 
                "description": "A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging."
            }, 
            {
                "arm_group_label": "2 Minute Delay", 
                "arm_group_type": "Active Comparator", 
                "description": "A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging."
            }, 
            {
                "arm_group_label": "4 Minute Delay", 
                "arm_group_type": "Active Comparator", 
                "description": "A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the consistency of quantitative peak stress\n      myocardial blood flow and myocardial blood flow reserve following a 10 second, 2 minute or 4\n      minute delay in beginning the rubidium-82 infusion post-Lexiscan (regadenoson) injection.\n      It is anticipated that there will be no or minimal difference between the three delay times."
        }, 
        "brief_title": "Characterization of Myocardial Blood Flow Measurements Using Lexiscan\u00ae\u2122 (Regadenoson) (Lexiscan\u00ae\u2122) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Myocardial Blood Flow Reserve", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recent normal clinically-indicated exercise myocardial perfusion SPECT, treadmill\n             maximal exercise test or exercise echocardiographic study\n\n          -  No change in symptoms between the exercise study and PET study\n\n          -  Capable of providing written informed consent\n\n          -  BMI 25-32 kg/m2\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus\n\n          -  Coronary Artery Calcium Score >25\n\n          -  Second and Third Degree Atrioventricular Node Block\n\n          -  Sinus Node Dysfunction\n\n          -  Recent Syncope of unknown etiology\n\n          -  Left ventricular hypertrophy per ECG or echocardiography\n\n          -  Slowed circulation times\n\n          -  Active wheezing or with acute asthmatic or bronchospastic attacks requiring changes\n             in therapy within the past 30 days.\n\n          -  Patients that have experienced a previous hypersensitivity reaction thought to be\n             related to Lexiscan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919450", 
            "org_study_id": "13-058"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "10 Second Delay", 
                    "2 Minute Delay", 
                    "4 Minute Delay"
                ], 
                "description": "Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.", 
                "intervention_name": "Regadenoson", 
                "intervention_type": "Drug", 
                "other_name": "Lexiscan"
            }, 
            {
                "arm_group_label": [
                    "10 Second Delay", 
                    "2 Minute Delay", 
                    "4 Minute Delay"
                ], 
                "description": "Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.", 
                "intervention_name": "Rubidium-82", 
                "intervention_type": "Radiation", 
                "other_name": "Cardio-Gen82"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Regadenoson"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PET", 
            "Lexiscan", 
            "Regadenoson", 
            "Rubidium", 
            "Blood Flow Reserve", 
            "Myocardial Perfusion", 
            "Quantitated Myocardial Perfusion"
        ], 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "scourter@cvit.com", 
                "last_name": "Staci A Courter, MA", 
                "phone": "816-531-2842", 
                "phone_ext": "107"
            }, 
            "contact_backup": {
                "email": "tbateman@cvit.com", 
                "last_name": "Timothy M Bateman, MD", 
                "phone": "816-751-8542"
            }, 
            "facility": {
                "address": {
                    "city": "Kansas City", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "64111"
                }, 
                "name": "Saint Luke's Hospital Imaging Center"
            }, 
            "investigator": {
                "last_name": "James A Case, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Characterization of Myocardial Blood Flow Measurements Using Lexiscan\u00ae\u2122 (Regadenoson) (Lexiscan\u00ae\u2122) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation", 
        "overall_contact": {
            "email": "scourter@cvit.com", 
            "last_name": "Staci A Courter, MA", 
            "phone": "816-531-2842", 
            "phone_ext": "107"
        }, 
        "overall_contact_backup": {
            "email": "tbateman@cvit.com", 
            "last_name": "Timothy M Bateman, MD", 
            "phone": "816-751-8542"
        }, 
        "overall_official": {
            "affiliation": "Cardiovascular Imaging Technologies", 
            "last_name": "Timothy M Bateman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.", 
                "measure": "Measure Quantitated Myocardial Perfusion Reserve after a 4 Minute Delay in Lexiscan (Regadenoson)", 
                "safety_issue": "No", 
                "time_frame": "4 minutes"
            }, 
            {
                "description": "The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.", 
                "measure": "Measure Quantitated Myocardial Perfusion Reserve after a 2 Minute Delay in Lexiscan (Regadenoson)", 
                "safety_issue": "No", 
                "time_frame": "2 mintues"
            }, 
            {
                "description": "The end-point of this study is to establish the mean and standard deviations of myocardial blood flow reserve values based on a 10 second, 2 minute and 4 minute delays between Lexiscan (Regadenoson) injection and the start of myocardial perfusion PET imaging.", 
                "measure": "Measure Quantitated Myocardial Perfusion Reserve after a 10 Second Delay in Lexiscan (Regadenoson)", 
                "safety_issue": "No", 
                "time_frame": "10 seconds"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919450"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cardiovascular Imaging Technologies", 
            "investigator_full_name": "Timothy M. Bateman, MD", 
            "investigator_title": "Medical Director", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Cardiovascular Imaging Technologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Timothy M. Bateman, MD", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}